- SteriGenics International, Inc. (NASDAQ: STER) is a leading provider of contract irradiation and sterilization services for health care and other markets
- TM Capital assisted SteriGenics in completing three strategic acquisitions which brought the company into new geographic markets, new sterilization technologies and new market applications
- TM Capital then assisted SteriGenics in completing its $214 million sale to Belgium-based Ion Beam Applications s.a. (BB: IBAB), a leading provider of particle accelerators for health care and other markets
- TM Capital also provided a fairness opinion in connection with the sale of SteriGenics to IBA
Client Testimonial
“TM Capital’s experience and healthcare industry expertise were key to the success of our acquisition program at SteriGenics, enabling us to broaden our technology range, enter new service categories, and expand our geographic reach. This successful growth culminated with TM Capital’s assistance in our sale of SteriGenics to an international acquiror at a strategic premium. I’ve clearly seen the benefit TM Capital’s resources can bring in building shareholder value.””James Clouser, President & CEO, SteriGenics